Transgenic SOD1 Models

Develop novel targeted Amyotrophic lateral Sclerosis (ALS) therapies by modelling early-stage symptomatic ALS with SOD1 mutations models

Mutations in the superoxide dismutase 1 (SOD1) gene are associated with familial amyotrophic lateral sclerosis (ALS). SOD1 mutations are thought to result in increased oxidative stress and protein aggregation, ultimately leading to a decline in motor function. Several ALS mouse models mimic the progressive loss of motor neurons in the motor cortex, brain stem, and spinal cord. 

InnoSer offers unique contract research services using several in vivo ALS models, including mutations in the SOD1 gene. Mice that express the human protein with ALS-related mutation have significant SOD1 aggregation, oxidative stress, and motor neuron loss. InnoSer has detected significant motor impairment in transgenic SOD1 mice. Behavioral changes can be detected already at young ages in SOD1 mice and are progressive.  

Take advantage of InnoSer’s preclinical research expertise, flexibility, and collaborative approach for your research. We support our clients in identifying new drugs or applications, characterizing their pharmacological properties, and conducting safety and efficacy testing with state-of-the-art readout capabilities and histopathological analysis. 

SOD1 model key characteristics:

  • Successful validation of multiple SOD1 models.
  • Early-onset of motor impairment.
  • Behavioural changes can be detected already at young ages in SOD1 mice and are progressive, making this model a valuable tool for efficacy testing of novel compounds. 

Find the right model for you.

Compare our model capabilities and discover which of our neurology platforms suits your research needs

Belgian based preclinical neurology CRO mouse models

Key readouts

Test the efficacy of your treatments in the following battery of behavioural tests:

Test the efficacy of your treatments with the following biological readouts:

  • MSD (e.g. cytokines) 
  • Immunohistochemistry (e.g. SOD1 aggregates, neuromuscular junction) 
  • Immunofluorescence and FISH

Related ALS Disease model options

Neurology Platform Overview

Highly relevant neurology models to facilitate preclinical drug development.

Transgenic TDP-43 Models

InnoSer offers services with several different transgenic tau models, which recapitulate the neurofibrilary tangle pathology of AD.

TDP-43 Seeding Models

InnoSer offers extensive preclinical research experience with TDP-43 seeds using patient-derived brain extracts.

AAALAC Accreditation

InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.


Animal Welfare

The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

Need more information?

If you have any questions about how we can help accelerate your research,

then let us know